ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
14.01
-0.10 (-0.71%)
At close: Nov 15, 2024, 4:00 PM
13.79
-0.22 (-1.57%)
After-hours: Nov 15, 2024, 5:08 PM EST
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ARS Pharmaceuticals stock have an average target of 24, with a low estimate of 19 and a high estimate of 30. The average target predicts an increase of 71.31% from the current stock price of 14.01.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 8, 2024.
Analyst Ratings
The average analyst rating for SPRY stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 5 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +114.13% | Oct 8, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $21 → $25 | Buy | Maintains | $21 → $25 | +78.44% | Sep 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +114.13% | Sep 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +114.13% | Sep 9, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $30 | Buy | Initiates | $30 | +114.13% | Aug 20, 2024 |
Financial Forecast
Revenue This Year
6.54M
from 30.00K
Increased by 21,686.67%
Revenue Next Year
69.06M
from 6.54M
Increased by 956.61%
EPS This Year
-0.66
from -0.57
EPS Next Year
-0.78
from -0.66
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 12.6M | 111.3M | 348.4M | ||
| Avg | 6.5M | 69.1M | 196.2M | ||
| Low | 2.3M | 32.8M | 63.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 41,900.0% | 1,602.9% | 404.5% | ||
| Avg | 21,686.7% | 956.6% | 184.1% | ||
| Low | 7,513.3% | 401.1% | -8.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.63 | -0.20 | 1.33 | |
| Avg | -0.66 | -0.78 | -0.08 | |
| Low | -0.67 | -1.47 | -0.89 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.